Cis Insulin Market By Product Type (Rapid-Acting Cis Insulin, Short-Acting Cis Insulin, Intermediate-Acting Cis Insulin, Long-Acting Cis Insulin, Ultra-Long-Acting Cis Insulin, Others), By Source (Human Recombinant Cis Insulin, Analog Cis Insulin), By Delivery Device (Vials & Syringes, Insulin Pens, Insulin Pumps, Others), By Route of Administration (Subcutaneous, Intravenous, Inhalation), By Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Others), and By End User (Hospitals, Specialty Diabetes Clinics, Ambulatory Surgical Centers (ASCs), Homecare Settings), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape Cis Insulin Market in the coming years?

The Cis Insulin Market accounted for USD 3.26 Billion in 2024 and USD 3.45 Billion in 2025 is expected to reach USD 6.08 Billion by 2035, growing at a CAGR of around 5.83% between 2025 and 2035. The Cis insulin market is the worldwide industry with the theme of manufacturing, distribution, and sale of Cis insulin, which is a bioengineered version of insulin structurally identical or close to the human one. In contrast to trans, or modified, insulin analogues, cis insulin rekindles the natural form of insulin molecules to achieve better efficacy and decreased side effects. The products distributed by this market are recombinant human insulin products, which are involved in the management of diabetes, including those governed by cost-effective options in parts of the world. Major growth factors are the increase in the number of diabetes cases, the need for cost-effective medicine, and the production improvement of biosimilar insulin. The key players are drug industries dealing with biologics and biosimilars.

What do industry experts say about the Cis Insulin market trends?

“The share of insulin produced in the Russian Federation in the Russian market in 2023 reached 95%.”

• Nikolai Bespalov, Development Director at RNC Pharma.

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Cis Insulin market?

How does increasing diabetes prevalence drive cis-insulin market demand?

The dynamics of the increased global rates of diabetes are the major force behind the demand for cis-insulin, which is one of the insulin therapies vital in the regulation of blood glucose levels in diabetic patients. The World Health Organisation suggests that there has been a nearly fourfold increase in the number of people with diabetes worldwide in the past three decades, and in 2021 alone, it is estimated that there are about 537 million diabetic adults globally. This explosion is mainly because of changes in lifestyles, urbanisation, and the ageing of the population.

According to the Centers for Disease Control and Prevention (CDC), approximately 37.3 million individuals, or 11.3% of the population, in the United States alone have diabetes, of which type 1 diabetes requires insulin treatment since its onset. Since insulin forms the core of treatment for type 1 and advanced type 2 diabetes, a higher diagnosis rate will simply translate to the growing requirements of cis-insulin products. The government health efforts to enhance access to diabetes care also serve to heighten demand in the market. The increase in this patient base and the increase in screening and diagnosis highlight the growing market opportunities that cis-insulin has across the world.

Can advancements in biotechnology enhance insulin production efficiency globally?

The field of biotechnology has greatly contributed to high efficiency in insulin production worldwide since biotechnology facilitates the cost-effective, scalable, and precise production of insulin. Advances in technology, such as recombinant DNA technology, enable large-scale purity and consistency of human-based insulin production as compared to archaic methods of animal sources. The World Health Organisation also claims that the insulin production costs lowered due to the use of biotechnology, which in turn made insulin more affordable in all parts of the world, including low- and middle-income regions where diabetes rates continue to increase.

A study by the National Institute of Diabetes, Digestive, and Kidney Diseases points out that synthetic biology and genetically modified strains of bacteria enhance insulin formulation stability as well as yield. The various enhancements help to meet the increasing global demand for insulin since over 537 million adults have diabetes globally, as per the International Diabetes Federation. Accordingly, contributions of biotechnology inventions are the most dominant factors that have driven the growth and productivity of the cis insulin market, which will help in the management of the illness across the world.

Are high treatment costs limiting accessibility to insulin products?

The high cost of treatment is a major obstacle hindering the availability of insulin products in the CIS insulin market. In this area, the prices of insulin can be considered unacceptably high, and many patients have to deal with financial difficulties related to them. As of a report published by the World Health Organisation in 2021, the affordability of insulin is a pressing concern, with most CIS countries spending a considerable amount of their healthcare funding to manage diabetes, so little money is left to make insulin widely accessible.

Moreover, one of the studies published in the International Diabetes Federation demonstrates that in the low-income and middle-income countries, such as several CIS members, up to 50% of reported cases indicate the economic reasons causing rationing or even skipping insulin injections. Such financial limitations limit the options for managing diabetes effectively, impairing the care and placing one at risk of complications. Insulin is not evenly subsidised in the region by the governments, a fact that worsens inaccessibility. Hence, insulin affordability is one of the crucial market growth and patient health outcome constraints in the CIS insulin market.

Can expansion into emerging markets unlock significant revenue potential?

Entering emerging markets presents CIS insulin manufacturers with a significant opportunity to generate substantial profits. The International Diabetes Federation (IDF) diabetes prevalence data indicates that countries in the low- and middle-income range are rapidly reaching their diabetes peak, with Uzbekistan and Kazakhstan having a high adult diabetes frequency of over 6%. The Russian Ministry of Health has reported an increase in domestic insulin demands, and the state programmes, such as the Federal Diabetes Program, annually finance diabetes treatment as part of the billion rubles.

Academic research has determined that in Russia, there are more than 11% of persons over the age of 40 with diabetes whose conditions have been untreated or under-treated (Ural Eye and Medical Study). Insulin has also been stressed by the World Health Organisation (WHO) as not being available to up to half of the population of some developing areas, particularly Central Asia. As healthcare investment increases and the demand goes unmet, CIS producers are in an excellent position to provide cheap insulin to these markets in terms of both public health and commercial growth.

How might digital healthcare integration improve insulin monitoring capabilities?

The use of digital healthcare in monitoring insulin in the CIS (Commonwealth of Independent States) region is an exciting notion that holds a major challenge in managing diabetes. The emergence of smart insulin pens and continuous glucose monitors (CGM) means patients are now able to get real-time feedback and receive data-led suggestions on their dosage of insulin. The World Health Organisation (WHO) suggests that digital health tools can help alleviate the chronic disease burden that is associated with illnesses such as diabetes through better treatment compliance and early detection of interventions. Among adults, more than 6% in Russia have diabetes (WHO Global Health Observatory), so care gaps in remote regions can be solved with the assistance of digital solutions.

A reduction in HbA1c by up to 0.5% has been demonstrated through studies (published in an academic journal such as The Lancet Digital Health). The infrastructures that are being established in support of remote monitoring via initiatives like the Russian “Digital Economy” programme are national digital health initiatives. The improvements may automate the process of insulin delivery, improve patient outcomes, and minimise complications, which is why they are important to the CIS insulin market in the future.

What are the key market segments in the Cis Insulin industry?

Based on the product type, the Cis Insulin Market has been classified into Rapid-Acting Cis Insulin, Short-Acting Cis Insulin, Intermediate-Acting Cis Insulin, Long-Acting Cis Insulin, Ultra-Long-Acting Cis Insulin, and Others. The most noticeable and important segment in the cis insulin market is the rapid-acting cis insulin segment. This can largely be attributed to its rapid action profile, which is similar to the response of the body's insulin in response to food intake, thus very useful to treat post-meal glucose surges. Rapid-acting insulin is more convenient and has better glycaemic control, as preferred by the patients and healthcare providers, due to its use in intensive insulin therapy. Moreover, its use has been enhanced by improvements in formulation and delivery systems, and this highly positions it in the market ahead of other kinds of insulin.

Based on the Source, the Cis Insulin Market has been classified into Human Recombinant Cis Insulin and Analog Cis Insulin. The Analogue Cis Insulin segment is most conspicuous and notable in the Cis Insulin market. Insulin analogues are genetically modified to bring the absorption, onset, and effects to be more predictable than conventional animal-free human recombinant insulin. This makes them the choice of many patients/medical professionals because it leads to improved control in blood sugar levels with minimal chances of hypoglycaemia. The reasons are improved efficacy, flexibility in dose, and the convenience for patients in having them, which has increased adoption rates, making analogue cis insulin the market-shaping segment.

Which regions are leading the Cis Insulin market, and why?

The North American cis-insulin market dominates, as it has developed infrastructure in terms of healthcare services, a powerful presence of leading pharmaceutical industries, and substantial investment in diabetes research and development. The United States is highly populated with diabetics, and this factor enhances uniform demand for effective insulin treatment.

The government support, the short era of approving new drugs, and the diabetes management knowledge prevailing throughout the region support the dominance of the region. Besides, reimbursement policies are positive, and innovative treatments are available, which makes adoption rates high. Clinical trials and other developments in drug delivery technology are not left behind in the region, as it maintains the lead as far as production and consumption are concerned.

The growth of government programmes meant to streamline the management of chronic diseases and educate patients contributes to the market growth in this region. It also has extensive distribution networks and makes the Cis Insulin products available promptly, even in the various rural and urban regions.

The Asia-Pacific CIS insulin market is leading because of a mixture of factors, which include a high and escalating diabetic population, growing health awareness, and speedy urbanisation. India and China are two of the nations with the greatest number of diabetic patients worldwide, which explains the steady growth in demand for insulin treatments.

The programmes developed by the government to increase access to affordable care and the widening of insurance coverage promote development in the market. There is also a production of biosimilar insulins by local pharmaceutical makers at lower prices, thereby boosting access. Further, the development of the healthcare infrastructure, increasing investments in R&D, and strategic partnerships with international actors also contribute to regional leadership.

The high number of patients, combined with the growing level of income and the implementation of more advanced treatment facilities, continue to cement the leadership of the Asia-Pacific region in the global market of cis insulin.

What does the competitive landscape of the Cis Insulin market look like?

The CIS insulin market is statistically competitive with the master players around the globe, namely, Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, and Novartis, who are the big shots of the market owing to their highly developed insulin formulations and global distribution chains. These firms keep on devoting funds to research so as to make effective and patient-friendly insulin therapy. Further, local producers in other countries like Russia continue to gain a stronger presence by using cost-effective production and by taking advantage of government policies that aim at decreasing the reliance on imports.

Such a dynamic is influencing the global players to revise their strategy, such as partnership or local manufacturing initiative, to maintain their market share. Moreover, the growing demand due to the growing rates of diabetes in the area is promoting growth and stimulating competitive prices and accessibility advancements. Overall, the market implies the presence of international experience and emerging regional competencies defining its future.

Cis Insulin Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Cis Insulin industry?

• In June 2025, Biocon’s Malaysian subsidiary surpassed the milestone of supplying over 100 million cartridges of recombinant human insulin to Malaysia’s Ministry of Health. This achievement has helped serve more than 345,000 patients and significantly strengthened the country’s domestic diabetes care infrastructure.
• In June 2024, Eli Lilly and Company (NYSE: LLY) revealed detailed results from SYNERGY-NASH, a phase 2 trial that involved 190 participants, both with and without type 2 diabetes. The trial studied the potential use of tirzepatide in adults who had biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis.

Report Coverage:

By Product Type

• Rapid-Acting Cis Insulin
• Short-Acting Cis Insulin
• Intermediate-Acting Cis Insulin
• Long-Acting Cis Insulin
• Ultra-Long-Acting Cis Insulin
• Others

By Source

• Human Recombinant Cis Insulin
• Analog Cis Insulin

By Delivery Device

• Vials & Syringes
• Insulin Pens
• Insulin Pumps
• Others

By Route of Administration

• Subcutaneous
• Intravenous
• Inhalation

By Application

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes
• Others

By End User

• Hospitals
• Specialty Diabetes Clinics
• Ambulatory Surgical Centers (ASCs)
• Homecare Settings

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Bristol-Myers Squibb
• Novartis
• Takeda Pharmaceuticals
• Boehringer Ingelheim
• Biocon
• Dongbao Enterprise Group
• Merck KGaA
• Oramed Pharmaceuticals
• Halozyme Therapeutics
• Wanbang Biopharma
• Xinbai Pharmaceutical
• Eli Lilly and Company
• Novo Nordisk
• Sanofi
• Merck & Co.

Frequently Asked Questions (FAQs)